Servier are delighted to announce the launch of the cardiovascular patient website – MyHealthPartner.ie
This platform responds to the need for a unique website for patients, with information on multiple risk factors, aimed at improving their understanding of their condition, for better adherence to treatment. It is an all-in-one web site developed with patients’ organization Global Heart Hub, therapeutic area experts, and nutritionists.
With MyHealthPartner.ie, patients will be able to understand their disease better through certified information and know more about their risk factors and symptoms. Patients will also be able to find answers to questions they may never have dared to ask their doctor.
The platform will also help patients take control and improve their
lifestyle. MyHealthPartner.ie includes personalized recipes adapted to each patient profile, with weekly meal plans to help patients cook new recipes every day. It also offers articles teaching patients how to relax, and details physical exercises to help them with their disease.
The website is designed to empower the patient in the management of their chronic disease, by providing information on the pathology and offering daily activities and recipes to reduce the risk of cardiovascular events.
New content is added to the website on a regular basis to encourages its members to introduce small changes to their lives.
MyHealthPartner.ie has been developed in consultation with The Global Heart Hub. Servier continues to put patients at the heart of their actions.
Should you require any further information, please contact Servier on 01 6638110.
Servier is a global pharmaceutical group governed by a non-profit Foundation, with its headquarters in Suresnes, France. With a strong international presence in 150 countries and a total revenue of 4.7 billion euros in 2021, Servier employs 21,800 people worldwide.
Servier is an independent group that invests over 20% of its brand-name revenue in Research and Development every year. To accelerate therapeutic innovation for the benefit of patients, the Group is committed to open and collaborative innovation with academic partners, pharmaceutical groups, and biotech companies. It also integrates the patient’s voice at the heart of its activities.
Corporate growth at Servier is based on a sustained commitment in cardiovascular and metabolic diseases, oncology, neuroscience, and immuno-inflammatory diseases. To promote access to healthcare for all, the Servier Group also offers a range of quality generic drugs covering most pathologies. In addition, Servier offers eHealth solutions beyond drug development.
More information: www.servier.ie
Read our Latest News